



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>A61K 39/12, 39/193, C12N 7/01</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/37911</b>  <b>(43) International Publication Date:</b> 3 September 1998 (03.09.98)
<b>(21) International Application Number:</b> PCT/US98/03894  <b>(22) International Filing Date:</b> 2 March 1998 (02.03.98)  <b>(30) Priority Data:</b> 08/807,445      28 February 1997 (28.02.97)      US 09/007,664      15 January 1998 (15.01.98)      US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</b> US      08/807,445 (CIP) Filed on      28 February 1997 (28.02.97) US      Not furnished (CIP) Filed on      15 January 1998 (15.01.98)  <b>(71) Applicants (for all designated States except US):</b> ORAVAX, INC. [US/US]; 38 Sidney Street, Cambridge, MA 02139 (US). ST. LOUIS UNIVERSITY [US/US]; 221 North Grand Boulevard, St. Louis, MO 63103 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> CHAMBERS, Thomas, J. [US/US]; 828 Twin Pine Drive, St. Louis, MO 63122 (US). MONATH, Thomas, P. [US/US]; 21 Finn Road, Harvard,		MA 01451 (US). GUIRAKHOO, Farshad [AT/US]; 39 Chestnut Street, Melrose, MA 02176 (US).  <b>(74) Agent:</b> CLARK, Paul, T.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> CHIMERIC FLAVIVIRUS VACCINES  <b>(57) Abstract</b>  A chimeric live, infectious, attenuated virus, containing a yellow fever virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated, so that functional prM-E protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that the prM-E protein of the second flavivirus is expressed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

## CHIMERIC FLAVIVIRUS VACCINES

### Background of the Invention

5           This invention relates to infectious, attenuated viruses useful as vaccines against diseases caused by flaviviruses.

          Several members of the flavivirus family pose current or potential threats to global public health. For example, Japanese encephalitis is a significant public health problem involving millions of at risk individuals in the  
10   Far East. Dengue virus, with an estimated annual incidence of 100 million cases of primary dengue fever and over 450,000 cases of dengue hemorrhagic fever worldwide, has emerged as the single most important arthropod-transmitted human disease. Other flaviviruses continue to cause endemic diseases of variable nature and have the potential to emerge into new areas as a  
15   result of changes in climate, vector populations, and environmental disturbances caused by human activity. These flaviviruses include, for example, St. Louis encephalitis virus, which causes sporadic, but serious acute disease in the midwest, southeast, and western United States; West Nile virus, which causes febrile illness, occasionally complicated by acute encephalitis,  
20   and is widely distributed throughout Africa, the Middle East, the former Soviet Union, and parts of Europe; Murray Valley encephalitis virus, which causes endemic nervous system disease in Australia; and Tick-borne encephalitis virus, which is distributed throughout the former Soviet Union and eastern Europe, where its ixodid tick vector is prevalent and responsible for a serious  
25   form of encephalitis in those regions.

          Hepatitis C virus (HCV) is another member of the flavivirus family, with a genome organization and replication strategy that are similar, but not

-2-

identical, to those of the flaviviruses mentioned above. HCV is transmitted mostly by parenteral exposure, is associated with chronic hepatitis that can progress to cirrhosis and hepatocellular carcinoma, and is a leading cause of liver disease requiring orthotopic transplantation in the United States.

5           The Flaviviridae family is distinct from the alphaviruses (*e.g.*, WEE, VEE, EEE, SFV, etc.) and currently contains three genera, the flaviviruses, the pestiviruses, and the hepatitis C viruses. Fully processed mature virions of flaviviruses contain three structural proteins, envelope (E), capsid (C), and membrane (M), and seven non-structural proteins (NS1, NS2A, NS2B, NS3,  
10 NS4A, NS4B, and NS5). Immature flavivirions found in infected cells contain pre-membrane (prM) protein, which is the precursor to the M protein.

          After binding of virions to host cell receptors, the E protein undergoes an irreversible conformational change upon exposure to the acidic pH of endosomes, causing fusion between the envelope bilayers of the virions  
15 and endocytic vesicles, thus releasing the viral genome into the host cytosol. PrM-containing tick-borne encephalitis (TBE) viruses are fusion-incompetent, indicating that proteolytic processing of prM is necessary for the generation of fusion-competent and fully infectious virions (Guirakhoo *et al.*, J. Gen. Virol. 72(Pt. 2):333-338, 1991). Using ammonium chloride late in virus replication  
20 cycle, prM-containing Murray Valley encephalitis (MVE) viruses were produced and shown to be fusion incompetent. By using sequence-specific peptides and monoclonal antibodies, it was demonstrated that prM interacts with amino acids 200-327 of the E protein. This interaction is necessary to protect the E protein from the irreversible conformational changes caused by  
25 maturation in the acidic vesicles of the exocytic pathway (Guirakhoo *et al.*, Virology 191:921-931, 1992).

          The cleavage of prM to M protein occurs shortly before release of

-3-

virions by a furin-like cellular protease (Stadler *et al.*, J. Virol. 71:8475-8481, 1997), which is necessary to activate hemagglutinating activity, fusogenic activity, and infectivity of virions. The M protein is cleaved from its precursor protein (prM) after the consensus sequence R-X-R/K-R (X is variable), and  
5 incorporated into the virus lipid envelope together with the E protein.

Cleavage sequences have been conserved not only within flaviviruses, but also within proteins of other, unrelated viruses, such as PE2 of murine coronaviruses, PE2 of alphaviruses, HA of influenza viruses, and p160 of retroviruses. Cleavage of the precursor protein is essential for virus  
10 infectivity, but not particle formation. It was shown that, in case of a TBE-dengue 4 chimera, a change in the prM cleavage site resulted in decreased neurovirulence of this chimera (Pletnev *et al.*, J. Virol. 67:4956-4963, 1993), consistent with the previous observation that efficient processing of the prM is necessary for full infectivity (Guirakhoo *et al.*, 1991, *supra*, 1992, *supra*; Heinz  
15 *et al.*, Virology 198:109-117, 1994). Antibodies to prM protein can mediate protective immunity, apparently due to neutralization of released virions that contain some uncleaved prM. The proteolytic cleavage site of the PE2 of VEE (4 amino acids) was deleted by site-directed mutagenesis of the infectious clone (Smith *et al.*, ASTMH meeting, December 7-11, 1997). Deletion mutants  
20 replicated with high efficiency and PE2 proteins were incorporated into particles. This mutant was evaluated in non-human primates and shown to cause 100% seroconversion and protected all immunized monkeys from a lethal challenge.

#### Summary of the Invention

25 The invention features chimeric, live, infectious, attenuated viruses that are each composed of:

-4-

(a) a first yellow fever virus (e.g., strain 17D), representing a live, attenuated vaccine virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated so that the functional prM-E protein of the first flavivirus is not expressed, and

5 (b) integrated into the genome of the first flavivirus, a nucleotide sequence encoding the viral envelope (prM-E proteins) of a second, different flavivirus, so that the prM-E protein of the second flavivirus is expressed from the altered genome of the first flavivirus.

The chimeric virus is thus composed of the genes and gene products  
10 responsible for intracellular replication belonging to the first flavivirus and the genes and gene products of the envelope of the second flavivirus. Since the viral envelope contains all of the antigenic determinants responsible for inducing neutralizing antibodies, the result of infection with the chimeric virus is that such antibodies are generated only against the second flavivirus.

15 A preferred live virus for use as the first flavivirus in the chimeric viruses of the invention is the yellow fever virus. At least one vaccine has already employed this live, attenuated virus; the vaccine is known as YF17D and has been used for human immunization for over 50 years. YF17D vaccine is described in a number of publications, including publications by Smithburn  
20 *et al.* ("Yellow Fever Vaccination," World Health Org., p. 238, 1956), and Freestone (*in Plotkin et al.*, (Eds.), *Vaccines*, 2<sup>nd</sup> edition, W.B. Saunders, Philadelphia, 1995). In addition, the yellow fever virus has been studied at the genetic level (Rice *et al.*, *Science* 229:726-733, 1985), and information correlating genotype and phenotype has been established (Marchevsky *et al.*,  
25 *Am. J. Trop. Med. Hyg.* 52:75-80, 1995).

Preferred flaviviruses for use as the second flavivirus in the chimeric viruses of the invention, and thus sources of immunizing antigen, include

-5-

Japanese Encephalitis (JE), Dengue (DEN, *e.g.*, any of Dengue types 1-4), Murray Valley Encephalitis (MVE), St. Louis Encephalitis (SLE), West Nile (WN), Tick-borne Encephalitis (TBE), and Hepatitis C (HCV) viruses.

Additional flaviviruses for use as the second flavivirus include Kunjin virus,  
5 Central European Encephalitis virus, Russian Spring-Summer Encephalitis virus, Powassan virus, Kyasanur Forest Disease virus, and Omsk Hemorrhagic Fever virus. In a preferred chimeric virus of the invention, the prM-E protein coding sequence of the second flavivirus is substituted into the prM-E protein coding sequence of the live yellow fever virus. In a preferred chimeric virus,  
10 the prM-E protein coding sequence is derived from an attenuated virus strain, such as a vaccine strain. Also, as is described further below, the prM portion of the protein can contain a mutation that prevents cleavage to generate mature membrane protein.

Also included in the invention are methods of preventing or treating  
15 flavivirus infection in a mammal, such as a human, by administering a chimeric flavivirus of the invention to the mammal; use of the chimeric flaviviruses of the invention in the preparation of medicaments for preventing or treating flavivirus infection; nucleic acid molecules encoding the chimeric flaviviruses of the invention; and methods of manufacturing the chimeric flaviviruses of the  
20 invention.

The invention provides several advantages. For example, because they are live and replicating, the chimeric viruses of the invention can be used to produce long-lasting protective immunity. Because the viruses have the replication genes of an attenuated virus (*e.g.*, Yellow Fever 17D), the resulting  
25 chimeric virus is attenuated to a degree that renders it safe for use in humans.

Other features and advantages of the invention will be apparent from the following detailed description, the drawings, and the claims.

-6-

Brief Description of the Drawings

Fig. 1 is a schematic representation of genetic manipulation steps that were carried out in order to construct a Yellow-Fever/Japanese Encephalitis (YF/JE) chimeric virus of the invention.

5 Fig. 2 is a set of growth curves for chimeric YF/JE viruses of the invention in cell cultures acceptable for preparation of a human vaccine.

Fig. 3 is a graph showing a growth comparison between RMS (Research Master Seed, YF/JE SA<sub>14</sub>-14-2) and YF-Vax in MRC-5 cells.

10 Fig. 4 is a graph and a table showing the results of a mouse neurovirulence analysis carried out with a YF/JE chimeric virus of the invention.

Fig. 5 is a schematic representation of a two plasmid system for generating chimeric YF/DEN-2 virus. The strategy is essentially as described for the YF/JE chimeric virus.

15 Fig. 6 is a schematic representation of the structure of modified YF clones designed to delete portions of the NS1 protein and/or express foreign proteins under control of an internal ribosome entry site (IRES). The figure shows only the E/NS1 region of the viral genome. A translational stop codon is introduced at the carboxyl terminus of the envelope (E) protein. Downstream  
20 translation is initiated within an intergenic open reading frame (ORF) by IRES-1, driving expression of foreign proteins (e.g., HCV proteins E1 and/or E2). The second IRES (IRES-2) controls translational initiation of the YF nonstructural region, in which nested, truncated NS1 proteins (e.g., NS1del-1, NS1del-2, or NS1del-3) are expressed. The size of the NS1 deletion is  
25 inversely proportional to that of the ORF linked to IRES-1.

Fig. 7 is a graph showing the neutralizing antibody response of mice immunized with a YF/JE SA<sub>14</sub>-14-2 chimeric vaccine.



-7-

Detailed Description

The invention provides chimeric flaviviruses that can be used in vaccination methods against flavivirus infection. Construction and analysis of chimeric flaviviruses of the invention, such as chimeras of yellow fever virus and Japanese Encephalitis (JE), Dengue types 1-4 (DEN 1-4), Murray Valley Encephalitis (MVE), St. Louis Encephalitis (SLE), West Nile (WN), Tick-borne Encephalitis (TBE), and Hepatitis C (HCV) viruses are described as follows.

Flavivirus proteins are produced by translation of a single, long open reading frame (encoding, *i.a.*, the structural proteins, capsid (C), pre-membrane (pr-M), and envelope (E), as well as non-structural proteins) and a complex series of post-translational proteolytic cleavages. The chimeric flaviviruses of the invention, as is discussed above, include those in which the pr-M and E proteins of one flavivirus have been replaced by the pr-M and E proteins of another flavivirus. Thus, creation of these chimeric flaviviruses involves the generation of novel junctions between the capsid and pre-membrane proteins, and the envelope protein and the non-structural region (NS1), of two different flaviviruses. Cleavage between each of these sets of proteins (C and pr-M, and E and NS1) occurs during the natural proteolytic processing of flavivirus proteins, and requires the presence of signal sequences flanking the junctions of the cleavage sites.

In the chimeric flaviviruses of the invention, it is preferred that the signal sequences of the viruses making up the chimeras are substantially maintained, so that proper cleavage between the C and pr-M and E and NS1 proteins can efficiently take place. These signal sequences have been maintained in the chimeras described below. Alternatively, any of numerous known signal sequences can be engineered to link the C and pre-M or E and

-8-

NS1 proteins of the chimeras (see, *e.g.*, von Heijne, Eur. J. Biochem. 133:17-21, 1983; von Heijne, J. Mol. Biol. 184:99-105, 1985) or, for example, using the known sequences for guidance, one skilled in the art can design additional signal sequences that can be used in the chimeras of the invention. Typically, for example, the signal sequence will include as its last residue an amino acid with a small, uncharged side chain, such as alanine, glycine, serine, cysteine, threonine, or glutamine. Other requirements of signal sequences are known in the art (see, *e.g.*, von Heijne, 1983, *supra*; von Heijne, 1985, *supra*). Also, the signal sequences of either of the viruses making up the chimera can be maintained or substantially maintained, so that proper cleavage takes place.

#### *Construction of cDNA Templates for Generation of YF/JE Chimeric Virus*

The derivation of full-length cDNA templates for YF/JE chimeras of the invention described below employed a strategy similar to that earlier workers used to regenerate YF17D from cDNA for molecular genetic analysis of YF replication. The strategy is described, *e.g.*, by Nestorowicz *et al.* (Virology 199:114-123, 1994).

Briefly, derivation of a YF/JE chimera of the invention involves the following. YF genomic sequences are propagated in two plasmids (YF5'3'IV and YFM5.2), which encode the YF sequences from nucleotides 1-2,276 and 8,279-10,861 (YF5'3'IV) and from 1,373-8,704 (YFM5.2) (Rice *et al.*, The New Biologist 1:285-296, 1989). Full-length cDNA templates are generated by ligation of appropriate restriction fragments derived from these plasmids. This method has been the most reliable for ensuring stable expression of YF sequences and generation of RNA transcripts of high specific infectivity.

Our strategy for construction of chimeras involves replacement of YF sequences within the YF5'3'IV and YFM5.2 plasmids by the corresponding

-9-

JE sequences from the start of the prM protein (nucleotide 478, amino acid 128) through the E/NS1 cleavage site (nucleotide 2,452, amino acid 817). In addition to cloning of JE cDNA, several steps were required to introduce or eliminate restriction sites in both the YF and JE sequences to permit *in vitro* ligation. The structure of the template for regenerating chimeric YF (C)/JE (prM-E) virus is shown in Fig. 4. A second chimera, encoding the entire JE structural region (C-prM-E) was engineered using a similar strategy.

#### *Molecular Cloning of the JE Virus Structural Region*

Clones of authentic JE structural protein genes were generated from the JE SA<sub>14</sub>-14-2 strain (JE live, attenuated vaccine strain), because the biological properties and molecular characterization of this strain are well-documented (see, *e.g.*, Eckels *et al.*, Vaccine 6:513-518, 1988; JE SA<sub>14</sub>-14-2 virus is available from the Centers for Disease Control, Fort Collins, Colorado and the Yale Arbovirus Research Unit, Yale University, New Haven, Connecticut, which are World Health Organization-designated Reference Centers for Arboviruses in the United States). JE SA<sub>14</sub>-14-2 virus at passage level PDK-5 was obtained and passaged in LLC-MK<sub>2</sub> cells to obtain sufficient amounts of virus for cDNA cloning. The strategy we used involved cloning the structural region in two pieces that overlap at an *NheI* site (JE nucleotide 1,125), which can then be used for *in vitro* ligation.

RNA was extracted from monolayers of infected LLC-MK<sub>2</sub> cells and first strand synthesis of negative sense cDNA was carried out using reverse transcriptase with a negative sense primer (JE nucleotide sequence 2,456-71) containing nested *XbaI* and *NarI* restriction sites for cloning initially into pBluescript II KS(+), and subsequently into YFM5.2(*NarI*), respectively. First strand cDNA synthesis was followed by PCR amplification of the JE sequence

-10-

from nucleotides 1,108-2,471 using the same negative sense primer and a positive sense primer (JE nucleotides sequence 1,108-1,130) containing nested *Xba*I and *Nsi*I restriction sites for cloning into pBluescript and YFM5.2(*Nar*I), respectively. JE sequences were verified by restriction enzyme digestion and nucleotide sequencing. The JE nucleotide sequence from nucleotides 1 to 1,130 was derived by PCR amplification of negative strand JE cDNA using a negative sense primer corresponding to JE nucleotides 1,116 to 1,130 and a positive sense primer corresponding to JE nucleotides 1 to 18, both containing an *Eco*RI restriction site. PCR fragments were cloned into pBluescript and JE sequences were verified by nucleotide sequencing. Together, this represents cloning of the JE sequence from nucleotides 1-2,471 (amino acids 1-792).

#### *Construction of YF5'3'TV/JE and YFM5.2/JE Derivatives*

To insert the C' terminus of the JE envelope protein at the YF E/NS1 cleavage site, a unique *Nar*I restriction site was introduced into the YFM5.2 plasmid by oligonucleotide-directed mutagenesis of the signalase sequence at the E/NS1 cleavage site (YF nucleotides 2,447-2,452, amino acids 816-817) to create YFM5.2(*Nar*I). Transcripts derived from templates incorporating this change were checked for infectivity and yielded a specific infectivity similar to the parental templates (approximately 100 plaque-forming units/250 nanograms of transcript). The JE sequence from nucleotides 1,108 to 2,471 was subcloned from several independent PCR-derived clones of pBluescript/JE into YFM5.2(*Nar*I) using the unique *Nsi*I and *Nar*I restriction sites. YF5'3'TV/JE clones containing the YF 5' untranslated region (nucleotides 1-118) adjacent to the JE prM-E region were derived by PCR amplification.

To derive sequences containing the junction of the YF capsid and JE prM, a negative sense chimeric primer spanning this region was used with a

-11-

positive sense primer corresponding to YF5'3'IV nucleotides 6,625-6,639 to generate PCR fragments that were then used as negative sense PCR primers in conjunction with a positive sense primer complementary to the pBluescript vector sequence upstream of the *EcoRI* site, to amplify the JE sequence

5 (encoded in reverse orientation in the pBluescript vector) from nucleotide 477 (N-terminus of the prM protein) through the *NheI* site at nucleotide 1,125. The resulting PCR fragments were inserted into the YF5'3'IV plasmid using the *NotI* and *EcoRI* restriction sites. This construct contains the SP6 promoter preceding the YF 5'-untranslated region, followed by the sequence: YF (C) JE

10 (prM-E), and contains the *NheI* site (JE nucleotide 1,125) required for *in vitro* ligation.

*Engineering YFM5.2 and YF5'3'IV to Contain Restriction Sites for in vitro Ligation*

In order to use the *NheI* site within the JE envelope sequence as a 5'

15 *in vitro* ligation site, a redundant *NheI* site in the YFM5.2 plasmid (nucleotide 5,459) was eliminated. This was accomplished by silent mutation of the YF sequence at nucleotide 5,461 (T→C; alanine, amino acid 1820). This site was incorporated into YFM5.2 by ligation of appropriate restriction fragments and introduced into YFM5.2(*NarI*)/JE by exchange of an *NsiI*/*NarI* fragment

20 encoding the chimeric YF/JE sequence.

To create a unique 3' restriction site for *in vitro* ligation, a *BspEI* site was engineered downstream of the *AatII* site normally used to generate full-length templates from YF5'3'IV and YFM5.2. (Multiple *AatII* sites are present in the JE structural sequence, precluding use of this site for *in vitro* ligation.)

25 The *BspEI* site was created by silent mutation of YF nucleotide 8,581 (A→C; serine, amino acid 2,860) and was introduced into YFM5.2 by exchange of

-12-

appropriate restriction fragments. The unique site was incorporated into YFM5.2/JE by exchange of the *XbaI/SphI* fragment and into the YF5'3'IV/JE(prM-E) plasmids by three-piece ligation of appropriate restriction fragments from these parent plasmids and from a derivative of YFM5.2 (*BspEI*) deleting the YF sequence between the *EcoRI* sites at nucleotides 1 and 6,912.

#### *Exchange of JE Nakayama cDNA into YF/JE Chimeric Plasmids*

Because of uncertainty about the capacity of the PCR-derived JE SA<sub>14</sub>14-2 structural region to function properly in the context of the chimeric virus, we used cDNA from a clone of the JE Nakayama strain that has been extensively characterized in expression experiments and for its capacity to induce protective immunity (see, *e.g.*, McIida *et al.*, Virology 158:348-360, 1987; the JE Nakayama strain is available from the Centers for Disease Control, Fort Collins, Colorado, and the Yale Arbovirus Research Unit, Yale University, New Haven, Connecticut). The Nakayama cDNA was inserted into the YF/JE chimeric plasmids using available restriction sites (*HindIII* to *PvuII* and *BpmI* to *MunI*) to replace the entire prM-E region in the two plasmid system except for a single amino acid, serine, at position 49, which was left intact in order to utilize the *NheI* site for *in vitro* ligation. The entire JE region in the Nakayama clone was sequenced to verify that the replaced cDNA was authentic (Table 2).

#### *Generation of Full-Length cDNA Templates, RNA Transfection, and Recovery of Infectious Virus*

Procedures for generating full-length cDNA templates are essentially as described in Rice *et al.* (The New Biologist 1:285-96, 1989) (see Fig. 1). In the case of chimeric templates, the plasmids YF5'3'IV/JE(prM-E) and

-13-

YFM5.2/JE are digested with *NheI/BspEI* and *in vitro* ligation is performed using 50 nanograms of purified fragments in the presence of T4 DNA ligase. The ligation products are linearized with *XhoI* to allow run-off transcription. SP6 transcripts are synthesized using 50 nanograms of purified template, quantitated by incorporation of <sup>3</sup>H-UTP, and integrity of the RNA is verified by non-denaturing agarose gel electrophoresis. Yields range from 5 to 10 micrograms of RNA per reaction using this procedure, most of which is present as full-length transcripts. Transfection of RNA transcripts in the presence of cationic liposomes is carried out as described by Rice *et al.* (*supra*) for YF17D.

10 In initial experiments, LLC-MK<sub>2</sub> cells were used for transfection and quantitation of virus, since we have determined the permissiveness for replication and plaque formation of the parental strains of YF and JE. Table 1 illustrates typical results of transfection experiments using Lipofectin (GIBCO/BRL) as a transfection vehicle. Vero cell lines have also been used

15 routinely for preparation of infectious virus stocks, characterization of labeled proteins, and neutralization tests.

#### *Nucleotide Sequencing of Chimeric cDNA Templates*

Plasmids containing the chimeric YF/JE cDNA were subjected to sequence analysis of the JE portion of the clones to identify the correct sequences of the SA<sub>14</sub>-14-2 and Nakayama envelope protein. The nucleotide sequence differences between these constructs in comparison to the reported sequences (McAda *et al.*, *supra*) are shown in Table 2.

20

#### *Structural and Biological Characterization of Chimeric YF/JE Viruses*

The genomic structure of chimeric YF/JE viruses recovered from transfection experiments was verified by RT/PCR-based analysis of viral RNA

25

-14-

harvested from infected cell monolayers. These experiments are performed in order to eliminate the possibility that virus stocks are contaminated during transfection procedures. For these experiments, first-pass virus was used to initiate a cycle of infection, in order to eliminate any possible artifacts generated by the presence of residual transfected viral RNA. Total RNA extracts of cells infected with either the YF/JE (prM-E)-SA<sub>14</sub>-14-2 or YF/JE (prM-E)-Nakayama chimera were subjected to RT/PCR using YF and JE-specific primers that allowed recovery of the entire structural region as two PCR products of approximately 1 kilobase in size. These products were then analyzed by restriction enzyme digestion using the predicted sites within the JE SA<sub>14</sub>-14-2 and Nakayama sequences that allow differentiation of these viruses. Using this approach, the viral RNA was demonstrated to be chimeric and the recovered viruses were verified to have the appropriate restriction sites. The actual C-prM boundary was then verified to be intact at the sequence level by cycle sequence analysis across the chimeric YF/JE C-prM junction.

The presence of the JE envelope protein in the two chimeras was verified by both immunoprecipitation with JE-specific antisera and by plaque reduction neutralization testing using YF and JE-specific antisera. Immunoprecipitation of <sup>35</sup>S-labeled extracts of LLC-MK<sub>2</sub> cells infected with the chimeras using a monoclonal antibody to the JE E protein showed that the JE envelope protein could be recovered as a 55 kD protein, whereas the same antisera failed to immunoprecipitate a protein from YF-infected cells. Both JE and YF hyperimmune sera demonstrated cross-reactivity for the two envelope proteins, but the size difference between the proteins (YF=53 kD, unglycosylated; JE=55 kD, glycosylated) could reproducibly be observed. Use of YF monoclonal antibodies was not satisfactory under the immunoprecipitation conditions, thus, the specificity was dependent on the JE



-15-

monoclonal antibodies in this analysis. Plaque reduction neutralization testing (PRNT) was performed on the chimeric viruses and the YF and JE SA<sub>14</sub>-14-2 viruses using YF and JE-specific hyperimmune ascitic fluid (ATCC) and YF-specific purified IgG (monoclonal antibody 2E10). Significant differences in the 50% plaque reduction titer of these antisera were observed for the chimeras when compared to the control viruses in these experiments (Table 3). Thus, epitopes required for neutralization are expressed in the infectious chimeric YF/JE viruses.

#### *Growth Properties in Cell Culture*

10           The growth capacity of the chimeras has been examined quantitatively in cell lines of both primate and mosquito origin. Fig. 2 illustrates the cumulative growth curves of the chimeras on LLC-MK<sub>2</sub> cells after low multiplicity infection (0.5 plaque-forming units/cell). In this experiment, YF5.2iv (cloned derivative) and JE SA<sub>14</sub>-14-2 (uncloned) viruses  
15           were used for comparison. Both chimeric viruses reached a maximal virus yield of approximately one log higher than either parental virus. In the case of the YF/JE SA<sub>14</sub>-14-2 chimera, the peak of virus production occurred 12 hours later than the YF/JE Nakayama chimera (50 hours vs. 38 hours). The YF/JE Nakayama chimera exhibited considerably more cytopathic effects than the  
20           YF/JE SA<sub>14</sub>-14-2 chimera on this cell line. A similar experiment was carried out in C6/36 cells after low multiplicity infection (0.5 plaque-forming units/cell). Fig. 2 also illustrates the growth kinetics of the viruses in this invertebrate cell line. Similar virus yields were obtained at all points used for virus harvest in this experiment, further substantiating the notion that chimeric  
25           viruses are not impaired in replication efficiency.

-16-

*Comparison of Growth Kinetics of the RMS (YF/JE SA<sub>14</sub>-14-2) with YF 17D Vaccine in MRC-5 Cells*

An experiment was performed to assess the ability of the vaccine candidate to propagate in a cell line acceptable for human vaccines.

- 5 Commercial Yellow Fever 17D vaccine (YF-Vax®) was obtained from Connaught Laboratories, Swiftwater, PA. MRC-5 (diploid human embryonal lung cells) were purchased from ATCC (171-CCL, Batch#: F-14308, passage 18) and grown in EMEM, 2 mM L-Gln, Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 10% FBS.
- 10 To compare growth kinetics of RMS (Research Master Seed, YF/JE SA<sub>14</sub>-14-2) with YF-Vax®, cells were grown to 90% confluency and infected with RMS or YF-Vax® at an MOI of 0.1 pfu. Since MRC-5 cells generally grow slowly, these cells were kept for 10 days post inoculation. Samples were frozen daily for 7-10 days and infectivity determined by plaque assay in Vero
- 15 cells.

YF-Vax® and the YF/JE chimera grew to modest titers in MRC-5 cells (Fig. 3). The peak titer was ~4.7 log<sub>10</sub> pfu for YF-Vax® achieved on the second day and was slightly lower, 4.5 log<sub>10</sub> pfu, for the RMS after 6 days.

*Neurovirulence Testing in Normal Adult Mice*

- 20 The virulence properties of the YF/JE SA<sub>14</sub>-14-2 chimera was analyzed in young adult mice by intracerebral inoculation. Groups of 10 mice (4 week old male and female ICR mice, 5 each per group) were inoculated with 10,000 plaque-forming units of the YF/JE SA<sub>14</sub>-14-2 chimera, YF5.2iv, or JE SA<sub>14</sub>-14-2 and observed daily for 3 weeks. The results of these experiments are illustrated
- 25 in Fig. 4. Mice receiving the YF5.2iv parent succumbed by approximately one

-17-

week post-inoculation. No mortality or illness was observed among mice receiving either the JE SA<sub>14</sub>-14-2 parent or the chimera. The inocula used for the experiments were titrated at the time of injection and a subgroup of the surviving mice were tested for the presence of neutralizing antibodies to confirm that infection had taken place. Among those tested, titers against the JE SA<sub>14</sub>-14-2 virus were similar for animals receiving either this strain or the chimera.

The results of additional experiments investigating the neurovirulence of the YF/JE SA<sub>14</sub>-14-2 chimera in mice are illustrated in Table 4. In these experiments, all of the mice inoculated with YF5.2iv died within 7-8 days. In contrast, none of the mice inoculated with YF/JE SA<sub>14</sub>-14-2 died during two weeks of post-inoculation observation.

The results of experiments investigating the neuroinvasiveness and pathogenesis of YF/JE chimeras are illustrated in Table 5. In these experiments, the chimeric viruses were inoculated into 3 week old mice at doses varying between 10,000 and 1 million plaque-forming units via the intraperitoneal route. None of the mice inoculated with YF/JE Nakayama or YF/JE SA<sub>14</sub>-14-2 died during three weeks of post-inoculation observation, indicating that the virus was incapable of causing illness after peripheral inoculation. Mice inoculated with YF/JE SA<sub>14</sub>-14-2 developed neutralizing antibodies against JE virus (Fig. 7).

#### *Construction of cDNA Templates for Generation of Yellow Fever/Dengue (YF/DEN) Chimeric Viruses*

Derivation of chimeric Yellow Fever/Dengue (YF/DEN) viruses is described as follows, which, in principle, is carried out the same as construction of the YF/JE chimera described above. Other flavivirus chimeras can be

-19-

MON310 furnished by Dr. Wright. PCR primers included a 5' primer flanking the *SphI* site and a 3' primer homologous to the DEN-2 nucleotides immediately upstream of the signalase site at the E/NSI junction and replacing the signalase site by substitutions that create a novel site, but also introduce a *NarI* site. The resulting 1,170 basepair PCR fragment was then introduced into YFM5.2(*NarI*[+]*SphI*[-]).

The 5' portion of the DEN-2 clone including the prM and amino terminal portion of the E protein was engineered into the YF5'3'IV plasmid using a chimeric PCR primer. The chimeric primer, incorporating the 3' end of negative-sense YF C protein and 5' end of DEN-2 prM protein, was used with a positive-sense primer flanking the SP6 promoter of the YF5'3'IV plasmid to generate a 771 basepair PCR product with a 20 base extension representing DEN-2 prM sequence. This PCR product was then used to prime the DEN-2 plasmid in conjunction with a 3' primer representing DEN-2 sequence 1,501-1,522 and flanking the *SphI*, to generate an 1,800 basepair final PCR product including the YF sequence from the *NotI* site through the SP6 promoter, YF 5' untranslated region, and YF C protein, contiguous with the DEN-2 prM-E1522 sequence. The PCR product was ligated into YF5'3'IV using *NotI* and *SphI* sites to yield the YF5'3'IV/DEN(prM-E) plasmid.

## 20 Construction of Chimeric Templates for Other Flaviviruses

Procedures for generating full-length cDNA templates encoding chimeric YF/MVE, YF/SLE, YF/WN, YF/TBE viruses are similar to those described above for the YF/DEN-2 system. Table 6 illustrates the features of the strategy for generating YF17D-based chimeric viruses. The unique restriction sites used for *in vitro* ligation, and the chimeric primers for engineering the C/prM and E/NSI junctions are also shown. Sources of cDNA

-21-

this protein may abrogate the immunity to YF associated with antibodies against NS1, and thus avoid problems with vector immunity if more than one chimeric vaccine was to be needed in a given recipient, or if a YF vaccine had been previously given or needed at a future point.

5           The strategy involves creating a series of in-frame deletions within the NS1 coding region of the YFM5.2 plasmid, in conjunction with engineering a translational termination codon at the end of E, and a series of two IRESs (internal ribosome entry sites). One IRES is immediately downstream of the termination codon and allows for expression of an open reading frame within  
10 the region between E and NS1. The second IRES initiates translation from truncated NS1 proteins, providing expression of the remainder of the YF nonstructural polyprotein. These derivatives are tested for recovery of infectious virus and the construct with the largest deletion is used for insertion of foreign sequences (*e.g.*, HCV proteins) in the first IRES. This particular  
15 construct can also serve as a basis for determining whether deletion of NS1 will affect vector-specific immunity in the context of YF/Flavivirus chimeric viruses expressing prM-E, as described above.

          The insertion of nucleotides encoding E1, E2, and/or E1 plus E2 HCV proteins is limited by the size of the deletion tolerated in the NS1 protein.  
20 Because of this, truncated HCV proteins can be used to enhance stability within the modified YF clone. The HCV proteins are engineered with an N-terminal signal sequence immediately following the IRES and a termination codon at the C terminus. This construction will direct the HCV proteins into the endoplasmic reticulum for secretion from the cell. The strategy for this  
25 construction is shown schematically in Fig. 6. Plasmids encoding HCV proteins of genotype I can be used for these constructions, for example, HCV plasmids obtained from Dr. Charles Rice at Washington University (Grakoui *et*

-22-

*al.*, J. Virology 67:1385-1395, 1993), who has expressed this region of the virus in processing systems and within a replication-complement full-length HCV clone.

*PrM cleavage deletion mutants as attenuating vaccine candidates for*  
5 *flaviviruses*

Additional chimeric viruses included in the invention contain mutations that prevent prM cleavage, such as mutations in the prM cleavage site. For example, the prM cleavage site in flavivirus infectious clones of interest, such as dengue, TBE, SLE, and others can be mutated by site-directed  
10 mutagenesis. Any or all of the amino acids in the cleavage site, as set forth above, can be deleted or substituted. A nucleic acid fragment containing the mutated prM-E genes can then be inserted into a yellow fever virus vector using the methods described above. The prM deletion can be used with or without other attenuating mutations, for example, mutations in the E protein, to  
15 be inserted into the yellow fever virus. These mutants have advantages over single substitution mutants as vaccine candidates, because it is almost impossible to revert the deleted sequence and restore virulence.

The following chimeric flaviviruses of the invention were deposited with the American Type Culture Collection (ATCC) in Rockville, Maryland,  
20 U.S.A. under the terms of the Budapest Treaty and granted a deposit date of January 6, 1998: Chimeric Yellow Fever 17D/Dengue Type 2 Virus (YF/DEN-2; ATCC accession number ATCC VR-2593) and Chimeric Yellow Fever 17D/Japanese Encephalitis SA<sub>14</sub>-14-2 Virus (YF/JE A1.3; ATCC accession number ATCC VR-2594).

-23-

**Table 1**Characterization of YF/JE chimeras

	Clone	Yield (µg)	Infectivity plaques/100ng LLC-MK2	PBS log titer VERO	RNAse log titer VERO	DNase log titer VERO
5	YF5.21v	5.5	15	7.2	0	7
	YF/JE-S	7.6	50	6.2	0	6.2
	YF/JE-N	7	60	5	0	5.4

**Table 2**Sequence comparison of JE strains and YF/JE chimeras

	Virus	E	E	E	E	E	E	E	E
		107	138	176	177	227	243	244	279
10	JE SA14-14-2	F	K	V	T	S	K	G	M
	YF/JE SA14-14-2	F	K	V	A	S	E	G	M
15	YF/JE NAK	L	E	I	T	P	E	E	K
	JE NAK	L	E	I	T	P	E	E	K
	JE SA14	L	E	I	T	S	E	G	K

**Table 3**Plaque reduction neutralization titers on YF/JE chimeras

	Virus	non-immune ascitic fluid	YF ascitic fluid	JE ascitic fluid	non-immune IgG	YF IgG
20	YF5.2iv	<1.3	3.7	<1.3	<2.2	>4.3
	JE SA14-14-2	<1.3	<1.3	3.4	<2.2	<2.2
	YF/JE SA14-14-2	<1.3	<1.3	3.1	<2.2	<1.9
25	YF/JE Nakayama	<1.3	<1.3	3.4	<2.2	<2.2

-24-

**Table 4**

Neurovirulence of YF/JE SA14-14-2 Chimera  
3 week old male ICR mice

		log dose I.C.	% Mortality	
	YF5.2iv	4	100	(7/7)
5	YF/JE SA 14-14-2	4	0	(0/7)
	YF/JE SA 14-14-2	5	0	(0/7)
	YF/JE SA14-14-2	6	0	(0/8)

**Table 5**

Neuroinvasiveness of YF/JE Chimeras  
3 week old male ICR mice

		log dose (intraperitoneal)	% mortality	
	YF/JE Nakayama	4	0	(0/5)
	YF/JE Nakayama	5	0	(0/4)
	YF/JE Nakayama	6	0	(0/4)
	YF/JE SA14-14-2	4	0	(0/5)
15	YF/JE SA14-14-2	5	0	(0/4)
	YF/JE SA14-14-2	6	0	(0/4)



-25-

Table 6

Engineering of YF/Flavivirus chimeras

	Virus	Chimeric C/prM junction <sup>1</sup>	Chimeric E/NS1 junction <sup>2</sup>	5' ligation <sup>3</sup>	3' ligation <sup>4</sup>	Sites <sup>5</sup> eliminated or (created)
5	YF/WN	X-cactgggagagcttgaaggtc (SEQ ID NO:1)	<u>aaagccagttgcagccgcggttaa</u> (SEQ ID NO:2)	<i>AatII</i>	<i>NsiI</i>	
	YF/DEN-1	X-aaggtagactgggtggctccc (SEQ ID NO:3)	<u>gatcctcagtaccacccgcggttaa</u> (SEQ ID NO:4)	<i>AatII</i>	<i>SphI</i>	<i>SphI</i> in DEN
10	YF/DEN-2	X-aaggtagattgggtgcattg (SEQ ID NO:5)	<u>aaccctcagtaccacccgcggttaa</u> (SEQ ID NO:6)	<i>AatII</i>	<i>SphI</i>	
	YF/DEN-3	X-aaggtgaattgaagtgtctta (SEQ ID NO:7)	<u>acccccagcaccacccgcggttaa</u> (SEQ ID NO:8)	<i>AatII</i>	<i>SphI</i>	<i>XhoI</i> in DEN ( <i>SphI</i> in DEN)
15	YF/DEN-4	X-aaaaggaacagttgtctcta (SEQ ID NO:9)	<u>acccgaagtgtcaaccgcggttaa</u> (SEQ ID NO:10)	<i>AatII</i>	<i>NsiI</i>	
	YF/SLE	X-aacgtgaatagttggatagtc (SEQ ID NO:11)	<u>accgtgtgtcgcacccgcggttaa</u> (SEQ ID NO:12)	<i>AatII</i>	<i>SphI</i>	<i>AatII</i> in SLE
	YF/MVE	X-aatttcgaaggtggaaggtc (SEQ ID NO:13)	<u>gaccggtgtttacagccgcggttaa</u> (SEQ ID NO:14)	<i>AatII</i>	<i>AgeI</i>	( <i>AgeI</i> in YF)
20	YF/TBE	X-tactgcgaacgacgttgccac (SEQ ID NO:15)	<u>actgggaacctcaccgcggttaa</u> (SEQ ID NO:16)	<i>AatII</i>	<i>AgeI</i>	( <i>AgeI</i> in YF)

1,2: The column illustrates the oligonucleotide used to generate chimeric YF/Flavivirus primers corresponding to the C/prM or E/NS1 junction. (See text). X = carboxyl terminal coding sequence of the YF capsid. The underlined region corresponds to the targeted heterologous sequence immediately upstream of the *NarI* site (antisense - ccgagg). This site allows insertion of PCR products into the Yfm5.2 (*NarI*) plasmid required for generating full-length cDNA templates. Other nucleotides are specific to the heterologous virus. Oligonucleotide primers are listed 5' to 3'.

3,4: The unique restriction sites used for creating restriction fragments that can be isolated and ligated *in vitro* to produce full-length chimeric cDNA templates are listed. Because some sequences do not contain convenient sites, engineering of appropriate sites is required in some cases (footnote 5).

5: In parentheses are the restriction enzyme sites that must be created either in the YF backbone or the heterologous virus to allow efficient *in vitro* ligation. Sites not in parentheses must be eliminated. All such modifications are done by silent mutagenesis of the cDNA for the respective clone. Blank spaces indicate that no modification of the cDNA clones is required.

### Other Embodiments

Other embodiments are within the following claims. For example, the prM-E protein genes of other flaviviruses of medical importance can be

-26-

inserted into the yellow fever vaccine virus backbone to produce vaccines against other medically important flaviviruses (see, *e.g.*, Monath *et al.*, "Flaviviruses," In *Virology*, Fields (ed.), Raven-Lippincott, New York, 1995, Volume I, 961-1034).

- 5 Examples of additional flaviviruses from which genes to be inserted into the chimeric vectors of the invention can be obtained include, *e.g.*, Kunjin, Central European Encephalitis, Russian Spring-Summer Encephalitis, Powassan, Kyasanur Forest Disease, and Omsk Hemorrhagic Fever viruses. In addition, genes from even more distantly related viruses can be inserted into the yellow  
10 fever vaccine virus to construct novel vaccines.

#### *Vaccine Production and Use*

- The vaccines of the invention are administered in amounts, and by using methods, that can readily be determined by persons of ordinary skill in this art. The vaccines can be administered and formulated, for example, in the  
15 same manner as the yellow fever 17D vaccine, *e.g.*, as a clarified suspension of infected chicken embryo tissue, or a fluid harvested from cell cultures infected with the chimeric yellow fever virus. Thus, the live, attenuated chimeric virus is formulated as a sterile aqueous solution containing between 100 and 1,000,000 infectious units (*e.g.*, plaque-forming units or tissue culture  
20 infectious doses) in a dose volume of 0.1 to 1.0 ml, to be administered by, for example, intramuscular, subcutaneous, or intradermal routes. In addition, because flaviviruses may be capable of infecting the human host *via* the mucosal routes, such as the oral route (Gresikova *et al.*, "Tick-borne Encephalitis," In *The Arboviruses, Ecology and Epidemiology*, Monath (ed.),  
25 CRC Press, Boca Raton, Florida, 1988, Volume IV, 177-203), the vaccine virus can be administered by a mucosal route to achieve a protective immune

-27-

response. The vaccine can be administered as a primary prophylactic agent in adults or children at risk of flavivirus infection. The vaccines can also be used as secondary agents for treating flavivirus-infected patients by stimulating an immune response against the flavivirus.

- 5           It may be desirable to use the yellow fever vaccine vector system for immunizing a host against one virus (for example, Japanese Encephalitis virus) and to later reimmunize the same individual against a second or third virus using a different chimeric construct. A significant advantage of the chimeric yellow fever system is that the vector will not elicit strong immunity to itself.
- 10   Nor will prior immunity to yellow fever virus preclude the use of the chimeric vaccine as a vector for heterologous gene expression. These advantages are due to the removal of the portion of the yellow fever vaccine E gene that encodes neutralizing (protective) antigens to yellow fever, and replacement
- 15   with another, heterologous gene that does not provide cross-protection against yellow fever. Although YF17D virus nonstructural proteins may play a role in protection, for example, by eliciting antibodies against NS1, which is involved in complement-dependent antibody mediated lysis of infected cells (Schlesinger *et al.*, J. Immunology 135:2805-2809, 1985), or by inducing
- 20   cytotoxic T cell responses to NS3 or other proteins of the virus, it is unlikely that these responses will abrogate the ability of a live virus vaccine to stimulate neutralizing antibodies. This is supported by the facts that (1) individuals who have been previously infected with JE virus respond to vaccination with YF17D similarly to persons without previous JE infection, and (2) individuals
- 25   who have previously received the YF17D vaccine respond to revaccination with a rise in neutralizing antibody titers (Sweet *et al.*, Am. J. Trop. Med. Hyg. 11:562-569, 1962). Thus, the chimeric vector can be used in populations that are immune to yellow fever because of prior natural infection or vaccination,

-28-

and can be used repeatedly, or to immunize simultaneously or sequentially with several different constructs, including yellow fever chimeras with inserts from, for example, Japanese Encephalitis, St. Louis Encephalitis, or West Nile viruses.

5           For vaccine applications, adjuvants that are known to those skilled in the art can be used. Adjuvants that can be used to enhance the immunogenicity of the chimeric vaccines include, for example, liposomal formulations, synthetic adjuvants, such as saponins (*e.g.*, QS21), muramyl dipeptide, monophosphoryl lipid A, or polyphosphazine. Although these adjuvants are  
10 typically used to enhance immune responses to inactivated vaccines, they can also be used with live vaccines. In the case of a chimeric vaccine delivered via a mucosal route, for example, orally, mucosal adjuvants such as the heat-labile toxin of *E. coli* (LT) or mutant derivations of LT are useful adjuvants. In addition, genes encoding cytokines that have adjuvant activities can be inserted  
15 into the yellow fever vectors. Thus, genes encoding cytokines, such as GM-CSF, IL-2, IL-12, IL-13, or IL-5, can be inserted together with heterologous flavivirus genes to produce a vaccine that results in enhanced immune responses, or to modulate immunity directed more specifically towards cellular, humoral, or mucosal responses. In addition to vaccine applications, as one  
20 skilled in the art can readily understand, the vectors of the invention can be used in gene therapy methods to introduce therapeutic gene products into a patient's cells. In these methods, genes encoding therapeutic gene products are inserted into the vectors, for example, in place of the gene encoding the prM-E protein.

25           An additional advantage of the yellow fever vector system is that flaviviruses replicate in the cytoplasm of cells, so that the virus replication strategy does not involve integration of the viral genome into the host cell

-29-

(Chambers *et al.* (1990) "Flavivirus Genome Organization, Expression, and Replication," In *Annual Review of Microbiology* 44:649-688), providing an important safety measure.

5 All references cited herein are incorporated by reference in their entirety.

What is claimed is:

-30-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION

- (i) APPLICANT: OraVax, Inc., et al.
  - (ii) TITLE OF THE INVENTION: CHIMERIC FLAVIVIRUS VACCINES
  - (iii) NUMBER OF SEQUENCES: 16
  - (iv) CORRESPONDENCE ADDRESS:
    - (A) ADDRESSEE: Clark & Elbing LLP
    - (B) STREET: 176 Federal Street
    - (C) CITY: Boston
    - (D) STATE: MA
    - (E) COUNTRY: USA
    - (F) ZIP: 02110
  - (v) COMPUTER READABLE FORM:
    - (A) MEDIUM TYPE: Diskette
    - (B) COMPUTER: IBM Compatible
    - (C) OPERATING SYSTEM: DOS
    - (D) SOFTWARE: FastSEQ for Windows Version 2.0
  - (vi) CURRENT APPLICATION DATA:
    - (A) APPLICATION NUMBER:
    - (B) FILING DATE: 02-MAR-98
    - (C) CLASSIFICATION:
  - (vii) PRIOR APPLICATION DATA:
    - (A) APPLICATION NUMBER: 08/807,445
    - (B) FILING DATE: 28-FEB-1997
  - (viii) PRIOR APPLICATION DATA:
    - (A) APPLICATION NUMBER: unknown
    - (B) FILING DATE: 15-JAN-98
  - (ix) ATTORNEY/AGENT INFORMATION:
    - (A) NAME: Clark, Paul T
    - (B) REGISTRATION NUMBER: 30,162
    - (C) REFERENCE/DOCKET NUMBER: 06132/033W02
  - (x) TELECOMMUNICATION INFORMATION:
    - (A) TELEPHONE: 617-428-0200
    - (B) TELEFAX: 617-428-7045
    - (C) TELEX:
- (2) INFORMATION FOR SEQ ID NO:1:

-31-

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CACTGGGAGA GCTTGAAGGT C

21

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AAAGCCAGTT GCAGCCGCGG TTAA

25

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AAGGTAGACT GGTGGGCTCC C

21

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

-32-

GATCCTCAGT ACCAACCGCG GTTTAA

26

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AAGGTAGATT GGTGTGCATT G

21

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AACCCTCAGT ACCACCGCG GTTTAA

26

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAGGTGAATT GAAGTGCTCT A

21

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear



-33-

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ACCCCCAGCA CCACCCGCGG TTAA

25

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AAAAGGAACA GTTGTTCTCT A

21

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ACCCGAAGTG TCAACGCGG TTAA

25

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AACGTGAATA GTTGATAGT C

21

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs

-34-

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ACCGTTGGTC GCACCCGCGG TTAA

25

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AATTCGAAA GGTGAAGGT C

21

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GACCGGTGTT TACAGCCGCG GTTTAA

26

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TACTGCGAAC GACGTTGCCA C

21

-35-

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ACTGGGAACC TCACCCGCGG TTAA

25

-36-

1. A chimeric live, infectious, attenuated virus, comprising:  
a yellow fever virus in which the nucleotide sequence encoding a prM-E protein is either deleted, truncated, or mutated so that functional yellow fever virus prM-E protein is not expressed, and  
5 integrated into the genome of said yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that said prM-E protein of said second flavivirus is expressed.
2. The chimeric virus of claim 1, wherein said second flavivirus is a Japanese Encephalitis (JE) virus.
- 10 3. The chimeric virus of claim 1, wherein said second flavivirus is a Dengue virus selected from the group consisting of Dengue types 1-4.
4. The chimeric virus of claim 1, wherein said second flavivirus is selected from the group consisting of a Murray Valley Encephalitis virus, a St. Louis Encephalitis virus, a West Nile virus, a Tick-borne Encephalitis virus, a  
15 Hepatitis C virus, a Kunjin virus, a Central European Encephalitis virus, a Russian Spring-Summer Encephalitis virus, a Powassan virus, a Kyasanur Forest Disease virus, and an Omsk Hemorrhagic Fever virus.
5. The chimeric virus of claim 1, wherein the nucleotide sequence encoding the prM-E protein of said second, different flavivirus replaces the  
20 nucleotide sequence encoding the prM-E protein of said yellow fever virus.
6. The chimeric virus of claim 1, wherein said nucleotide sequence encoding said prM-E protein of said second, different flavivirus comprises a

-37-

mutation that prevents prM cleavage to produce M protein.

7. The chimeric virus of claim 1, wherein the signal sequences at the C/prM and E/NS1 junctions are maintained in construction of said chimeric flavivirus.

5           8. Use of a chimeric live, infectious, attenuated virus in the preparation of a medicament for preventing or treating flavivirus infection in a patient, wherein the chimeric, live, infectious attenuated virus comprises a yellow fever virus in which the nucleotide sequence encoding a prM-E protein is either deleted, truncated, or mutated so that functional yellow  
10 fever virus prM-E protein is not expressed, and integrated into the genome of said yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that said prM-E protein of said second flavivirus is expressed.

9. The use of claim 8, wherein said second flavivirus is a Japanese  
15 Encephalitis (JE) virus.

10. The use of claim 8, wherein said second flavivirus is a Dengue virus selected from the group consisting of Dengue types 1-4.

11. The use of claim 8, wherein said second flavivirus is selected from the group consisting of a Murray Valley Encephalitis virus, a St. Louis  
20 Encephalitis virus, a West Nile virus, a Tick-borne Encephalitis virus, a Hepatitis C virus, a Kunjin virus, a Central European Encephalitis virus, a Russian Spring-Summer Encephalitis virus, a Powassan virus, a Kyasanur

-38-

Forest Disease virus, and an Omsk Hemorrhagic Fever virus.

12. The use of claim 8, wherein the nucleotide sequence encoding the prM-E protein of said second, different flavivirus replaces the nucleotide sequence encoding the prM-E protein of said yellow fever virus.

5           13. The use of claim 8, wherein said nucleotide sequence encoding said prM-E protein of said second, different flavivirus comprises a mutation that prevents prM cleavage to produce M protein.

14. The use of claim 8, wherein the signal sequences at the C/prM and E/NS1 junctions are maintained in construction of said chimeric flavivirus.

10           15. A nucleic acid molecule encoding a chimeric live, infectious, attenuated virus, said virus comprising:  
            a yellow fever virus in which the nucleotide sequence encoding a prM-E protein is either deleted, truncated, or mutated so that functional yellow fever virus prM-E protein is not expressed, and  
15           integrated into the genome of said yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that said prM-E protein of said second flavivirus is expressed.

16. The nucleic acid molecule of claim 15, wherein said second flavivirus is a Japanese Encephalitis (JE) virus.

20           17. The nucleic acid molecule of claim 15, wherein said second flavivirus is a Dengue virus selected from the group consisting of Dengue types

-39-

1-4.

18. The nucleic molecule of claim 15, wherein said second flavivirus is selected from the group consisting of a Murray Valley Encephalitis virus, a St. Louis Encephalitis virus, a West Nile virus, a Tick-borne
- 5 Encephalitis virus, a Hepatitis C virus, a Kunjin virus, a Central European Encephalitis virus, a Russian Spring-Summer Encephalitis virus, a Powassan virus, a Kyasanur Forest Disease virus, and an Omsk Hemorrhagic Fever virus.

19. The nucleic acid molecule of claim 15, wherein the nucleotide sequence encoding the prM-E protein of said second, different flavivirus
- 10 replaces the nucleotide sequence encoding the prM-E protein of said yellow fever virus.

20. The nucleic acid molecule of claim 15, wherein said nucleotide sequence encoding said prM-E protein of said second, different flavivirus comprises a mutation that prevents prM cleavage to produce M protein.

- 15 21. The nucleic acid molecule of claim 15, wherein the signal sequences at the C/prM and E/NS1 junctions are maintained in construction of said chimeric flavivirus.

1/7




FIG. 1



2/7






FIG. 2

3/7




Growth comparison between RMS and YF-Vax in MRC-5 cells.

Fig. 3

## Mouse neurovirulence analysis

MICE: 4 week old ICR males/females  
 VIRUS DOSE:  $10^4$  pfu intracerebrally



Virus	Survival	P
YF52iv	0/12 (0%)	-
JE SA <sub>14-14-2</sub>	12/12 (100%)	<0.001
YF/JE SA <sub>14-14-2</sub>	13/13 (100%)	<0.001

Fig. 4




Fig. 5

Structure of modified YF clones expressing  
E/NS1 intergenic open reading frames




Fig. 6

7/7

Neutralizing antibody response  
to YF/JE SA 14-14-2 chimeric vaccine  
(3-week old mice immunized, samples for testing taken at 6 weeks)




Fig. 7

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/03894

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 39/12, 39/193; C12N 7/01

US CL :424/199.1, 218.1; 435/235.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/199.1, 218.1; 435/235.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, EMBASE

search terms:Japanese encephalitis, attenuat?, yellow fever, chimer?, dengue, flavivir?

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BRAY et al. Construction of Intertypic Chimeric dengue Viruses by Substitution of Structural Protein Genes. November 1991. Proc. Natl. Acad. Sci., USA. Vol. 88, pages 10342-10346, see entire document.	1-21
Y	VENUGOPAL et al. Towards a New Generation of Flavivirus Vaccines. Vaccine. 1994. Vol. 12, No. 11, pages 966-975, see entire document.	1-21
Y	MARCHEVSKY et al. Phenotypic Analysis of Yellow Fever Virus Derived From Complementary DNA. American J Tropical Medicine & Hygiene. 1995. Vol. 52, No. 1, pages 75-80, see entire document..	1-21



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	
*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E* earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means	*A* document member of the same patent family
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 APRIL 1998

Date of mailing of the international search report

23 JUN 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MP WOODWARD

Telephone No. (703) 308-0196

**THIS PAGE BLANK (USPTO)**